AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM HEREDITARY ANGIOEDEMA (HAE) MEDICATIONS

Fax back to: 1-855-799-2553

If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.

MEMBER INFORMATION	
Last Name:	First Name:
Medicaid ID Number:	Date of Birth:
Gender: Male Female	Weight in Kilograms:
PRESCRIBER INFORMATION	
Last Name:	First Name:
NPI Number:	
Phone Number:	Fax Number:
DRUG INFORMATION	
Preferred Medications (Quantity Limits):	
☐ Cinryze® – 20 vials per 34 days ☐ Berinert® – 4 vials per attack (plus 4 for emergency)	
icatibant: 1 dose per attack (plus 1 for emergency)	
Kalbitor® – 3 vials per attack (plus 3 for emergency) (see Black Box warning below)	
Because of the risk of anaphylaxis, KALBITOR® should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.	
Non-Preferred Medications (Quantity Limits):	
Firazyr®: 1 dose per attack (plus 1 for emergency) Orladeyo®: 34 capsules per 34 days	
Ruconest®: 2 vials per attack (plus 2 for emergency) Takhzyro®: 2 vials per 28 days	
Haegarda®: 2,000 IU SDV kit (16 kits per 28 days) and 3,000 IU SDV kit (8 kits per 28 days)	
Drug Name/Form:	
Strength:	
Dosing Frequency:	
Length of Therapy:	
Quantity per Day:	

C10431-A 11-2023 Revised: 09/21/2023 | Effective: 01/01/2024 Page 1 of 2

(Form continued on next page.)

AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM: Hereditary Angioedema (HAE) Medications Member's Last Name: Member's First Name: **DIAGNOSIS AND MEDICAL INFORMATION** 1. Has the recipient's diagnosis of HAE been confirmed by C1 inhibitor (C1-INh) deficiency or dysfunction (type 1 or 2 HAE) as documented by one of the following: C1-INh antigenic level below the lower limit of normal; OR C1-INh functional level below the lower limit of normal? Yes No 2. Was the medication prescribed by, or in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics? Yes No TREATMENT OF ACUTE HAE ATTACKS Berinert® (C1 esterase inhibitor), Firazyr® (icatibant), icatibant, Kalbitor® (ecallantide), Ruconest® (C1 esterase inhibitor), Sajazir™ (icatibant) 1. Will the requested medication be used as mono therapy to treat acute HAE attacks? Yes PROPHYLAXIS OF HAE ATTACKS Cinryze® (C1 esterase inhibitor), Haegarda® (C1 estarase inhibitor), Orladeyo® (berotralstat), Takhzyro® (ianadelumab-flyo) 1. Will the requested medication be used for prophylaxis of HAE attacks? Yes No Prescriber Signature (Required) Date By signature, the physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; incomplete forms will delay the PA process.

Submission of documentation does NOT guarantee coverage.

C10431-A 11-2023 Revised: 09/21/2023 | Effective: 01/01/2024 Page 1 of 2